Related Experiment Video
Updated: Apr 30, 2026
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Current vaccine trials in glioblastoma: a review
Linda W Xu1, Kevin K H Chow1, Michael Lim2
1Department of Neurosurgery, Stanford University Medical Center, Stanford, CA 94304, USA.
Abstract:
Glioblastoma (GBM) is the most common primary brain tumor, and despite aggressive therapy with surgery, radiation, and chemotherapy, average survival remains at about 1.5 years. The highly infiltrative and invasive nature of GBM requires that alternative treatments for this disease be widespread and targeted to tumor cells. Immunotherapy in the form of tumor vaccines has the potential to meet this need. Vaccines against GBM hold the promise of triggering specific and systemic antitumor immune responses that may be the key to eradicating this unrelenting cancer. In this review, we will discuss past and present clinical trials of various GBM vaccines and their potential impact on the future care of GBM patients. There have been many promising phase I and phase II GBM vaccine studies that have led to ongoing and upcoming phase III trials. If the results of these randomized trials show a survival benefit, immunotherapy will become a standard part of the treatment of this devastating disease.
Insights
Glioblastoma (GBM) vaccines show promise for treating this aggressive brain cancer. Ongoing clinical trials aim to determine if immunotherapy can improve survival rates for GBM patients.
Area of Science:
- Neuro-oncology
- Immunology
- Clinical Trials
Background:
- Glioblastoma (GBM) is the most aggressive primary brain tumor with poor prognosis despite standard treatments.
- GBM's invasive nature necessitates novel, targeted therapeutic strategies.
- Immunotherapy, specifically tumor vaccines, offers a promising approach to combat GBM.
Purpose of the Study:
- To review past and present clinical trials of Glioblastoma vaccines.
- To evaluate the potential impact of GBM vaccines on future patient care.
- To assess the role of immunotherapy in treating Glioblastoma.
Main Methods:
- Review of existing clinical trial data for Glioblastoma vaccines.
- Analysis of Phase I, II, and III trial outcomes.
- Evaluation of immunotherapy's efficacy in preclinical and clinical settings.
Main Results:
- Numerous Phase I and II Glioblastoma vaccine studies have yielded promising results.
- These positive outcomes have led to the initiation of several Phase III clinical trials.
- Early data suggests the potential for specific and systemic antitumor immune responses.
Conclusions:
- Glioblastoma vaccines represent a significant advancement in brain tumor immunotherapy.
- Successful Phase III trials could establish immunotherapy as a standard treatment for Glioblastoma.
- Further research and clinical validation are crucial for optimizing GBM vaccine therapies.
